520 related articles for article (PubMed ID: 18760581)
41. Can outpatient pharmacy data identify persons with undiagnosed COPD?
Mapel DW; Petersen H; Roberts MH; Hurley JS; Frost FJ; Marton JP
Am J Manag Care; 2010 Jul; 16(7):505-12. PubMed ID: 20645666
[TBL] [Abstract][Full Text] [Related]
42. Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone.
Gerhardsson de Verdier M; Andersson M; Kern DM; Zhou S; Tunceli O
Value Health; 2015 Sep; 18(6):759-66. PubMed ID: 26409602
[TBL] [Abstract][Full Text] [Related]
43. Healthcare utilization and costs among chronic bronchitis patients treated with maintenance medications from a US managed care population.
AbuDagga A; Sun SX; Tan H; Solem CT
J Med Econ; 2013; 16(3):421-9. PubMed ID: 23336296
[TBL] [Abstract][Full Text] [Related]
44. Vesicoureteral reflux and ureteroceles.
Pohl HG; Joyce GF; Wise M; Cilento BG
J Urol; 2007 May; 177(5):1659-66. PubMed ID: 17437779
[TBL] [Abstract][Full Text] [Related]
45. Incremental direct expenditure of treating asthma in the United States.
Kamble S; Bharmal M
J Asthma; 2009 Feb; 46(1):73-80. PubMed ID: 19191142
[TBL] [Abstract][Full Text] [Related]
46. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991.
Jacobson L; Hertzman P; Löfdahl CG; Skoogh BE; Lindgren B
Respir Med; 2000 Mar; 94(3):247-55. PubMed ID: 10783936
[TBL] [Abstract][Full Text] [Related]
47. Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.
Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
Appl Health Econ Health Policy; 2011 Nov; 9(6):377-87. PubMed ID: 21888449
[TBL] [Abstract][Full Text] [Related]
48. Gender differences in emergency department patients with chronic obstructive pulmonary disease exacerbation.
Cydulka RK; Rowe BH; Clark S; Emerman CL; Rimm AR; Camargo CA
Acad Emerg Med; 2005 Dec; 12(12):1173-9. PubMed ID: 16282511
[TBL] [Abstract][Full Text] [Related]
49. Health services use and health care costs of obese and nonobese individuals.
Raebel MA; Malone DC; Conner DA; Xu S; Porter JA; Lanty FA
Arch Intern Med; 2004 Oct; 164(19):2135-40. PubMed ID: 15505127
[TBL] [Abstract][Full Text] [Related]
50. Economic burden and co-morbidities of atrial fibrillation in a privately insured population.
Wu EQ; Birnbaum HG; Mareva M; Tuttle E; Castor AR; Jackman W; Ruskin J
Curr Med Res Opin; 2005 Oct; 21(10):1693-9. PubMed ID: 16238910
[TBL] [Abstract][Full Text] [Related]
51. Trends in COPD mortality and hospitalizations in countries and regions of Asia-Pacific.
Tan WC; Seale P; Ip M; Shim YS; Chiang CH; Ng TP; Abisheganadan J; Charoenratanakul S; DeGuia T; Mahayiddin A; Mangunnegoro H; Xu YJ; Zhong NS
Respirology; 2009 Jan; 14(1):90-7. PubMed ID: 19144054
[TBL] [Abstract][Full Text] [Related]
52. Finasteride versus dutasteride: a real-world economic evaluation.
Fenter TC; Runken MC; Black L; Eaddy M
Am J Manag Care; 2007 Feb; 13 Suppl 1():S23-8. PubMed ID: 17295602
[TBL] [Abstract][Full Text] [Related]
53. Estimation of economic costs associated with transfusion dependence in adults with MDS.
Frytak JR; Henk HJ; De Castro CM; Halpern R; Nelson M
Curr Med Res Opin; 2009 Aug; 25(8):1941-51. PubMed ID: 19552620
[TBL] [Abstract][Full Text] [Related]
54. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS
Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224
[TBL] [Abstract][Full Text] [Related]
55. Psoriasis and chronic obstructive pulmonary disease: a case-control study.
Dreiher J; Weitzman D; Shapiro J; Davidovici B; Cohen AD
Br J Dermatol; 2008 Sep; 159(4):956-60. PubMed ID: 18637897
[TBL] [Abstract][Full Text] [Related]
56. Predicting the costs of managing patients with chronic obstructive pulmonary disease.
Mapel DW; McMillan GP; Frost FJ; Hurley JS; Picchi MA; Lydick E; Spencer MD
Respir Med; 2005 Oct; 99(10):1325-33. PubMed ID: 16140232
[TBL] [Abstract][Full Text] [Related]
57. Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes).
Dal Negro RW; Tognella S; Tosatto R; Dionisi M; Turco P; Donner CF
Respir Med; 2008 Jan; 102(1):92-101. PubMed ID: 17881206
[TBL] [Abstract][Full Text] [Related]
58. Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer.
Au DH; Udris EM; Fihn SD; McDonell MB; Curtis JR
Arch Intern Med; 2006 Feb; 166(3):326-31. PubMed ID: 16476873
[TBL] [Abstract][Full Text] [Related]
59. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
